First Line Therapy for Metastatic Pancreatic Cancer
DOI:
https://doi.org/10.6092/1590-8577/1667Keywords:
130-nm albumin-bound paclitaxel, CA-19-9 Antigen, oxaliplatin, Pancreatic NeoplasmsAbstract
Metastatic pancreatic cancer remains a difficult disease to treat; however, there are more new drug combinations on the horizon each week. We will discuss the results of the MPACT trial presented at the 2013 ASCO Annual Meeting (Abstracts #4005, #4058, and #4059) and compare to the 2011 FOLFIRINOX data.
Image: MPACT control and experimental arms.
Downloads
References
Cancer Facts and Figures 2013. American Cancer Society
Burris HA, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-13, 1997.
Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-25, 2011.
Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, et al. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol 31, 2013(Suppl): Abstract #4005.
Komar G, et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009; 15:5511-7.
5. Von Hoff D, et al. Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial. JCO 2011;29:4548-4554.
Frese K, et al. nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery 2012; 261-269.
Chiorean EG, Von Hoff DD, Ervin TJ, Arena FP, Infante JR, Bathini VG, et al. CA 19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC). J Clin Oncol 31, 2013(Suppl): Abstract #4058.
Moore MJ, Von Hoff DD, Ervin TJArena FP, Chiorean EG, Infante JR, et al. Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC). J Clin Oncol 31, 2013(Suppl): Abstract #4059.
